Well Pharmaceutical(SH:603351) Shanxi Securities·2025-08-26 11:24Investment Rating - The report assigns a "Buy-B" rating to the company, indicating a positive outlook for its stock performance in the near term [1][9]. Core Insights - The company has shown a stable operational performance driven by its synthetic lubricating base oil and pharmaceutical excipients segments. Despite a slight decline in revenue and net profit in the first half of 2025, the overall business remains resilient [4][5]. - The company is focusing on high-value new products in the pharmaceutical excipients sector, with ongoing research and development efforts aimed at innovative formulations and applications [6][9]. - The financial projections indicate a growth trajectory for net profits from 1.7 billion yuan in 2025 to 3.3 billion yuan by 2027, with corresponding price-to-earnings ratios decreasing from 24 to 13 times [7][11]. Financial Performance Summary - For the first half of 2025, the company reported total revenue of 674 million yuan, a year-on-year decrease of 2.1%, and a net profit of 73 million yuan, down 7.77% year-on-year [3]. - The revenue breakdown for major product segments in H1 2025 includes synthetic lubricating base oil at 464 million yuan (down 3.5%), pharmaceutical excipients at 164 million yuan (down 6.0%), and other products showing significant growth [4]. - The overall gross margin for H1 2025 was 28.08%, reflecting a year-on-year increase of 2.1 percentage points, while the net margin was 10.58%, a slight decrease of 0.7 percentage points [4]. Market Position and Strategy - The company is deeply engaged in the synthetic lubricating base oil market, particularly in the refrigeration compressor oil sector, benefiting from the growing demand in commercial refrigeration and new energy vehicles [5][9]. - The strategic focus on emerging industries such as new energy, new materials, and high-end equipment positions the company for future growth opportunities [5][9].